<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132860">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01972178</url>
  </required_header>
  <id_info>
    <org_study_id>CTN 4016 13202</org_study_id>
    <nct_id>NCT01972178</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 600 mg Once Daily Versus Placebo in Statin-Stable Subjects With Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pronova BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pronova BioPharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is

        -  To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood
           lipids and lipoprotein parameter from baseline after 12 weeks of treatment

        -  To evaluate the safety of PRC-4016 as assessed by adverse events and other safety
           parameters
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      6-8 weeks screening period with diet/lifestyle stabilization and lipid qualification
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent change in Non-HDL-C from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in triglycerides from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL-C from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-C from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VLDL-C from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ApoA1 from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ApoB from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lp-PLA2 from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hsCRP from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in red blood cell content of EPA and DHA from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Resistance (HOMA) from baseline to Week 12</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>PRC-4016</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRC-4016, oral administration once daily, capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, oral administration once daily, capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRC-4016</intervention_name>
    <arm_group_label>PRC-4016</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Fasting triglycerides 200-499 mg/dl

          -  Non-HDL-C &gt; 130 mg/dl

          -  Stable statin treatment

        Exclusion Criteria:

          -  Type I diabetes or uncontrolled type II diabetes

          -  Recent cardiovascular or coronary event

          -  History of pancreatitis

          -  History or evidence of major and clinically significant diseases that would interfere
             with the conduct of the study or interpretation of data

          -  Uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pål Nord, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Pronova BioPharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pål Nord, MD, MPH</last_name>
    <phone>+47 95748933</phone>
    <email>pal.nord@pronova.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Runar Vige, M.Sc., MBA</last_name>
    <phone>+47 99168298</phone>
    <email>runar.vige@pronova.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Affiliated Research Center, Inc.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Carter, MD</last_name>
      <phone>256-564-7264</phone>
      <email>mcarter@marc-research.com</email>
    </contact>
    <investigator>
      <last_name>Michael Carter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terence Hart, MD</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35662</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence Hart, MD</last_name>
      <phone>256-386-1105</phone>
      <email>terhart@hiwaay.net</email>
    </contact>
    <investigator>
      <last_name>Terence Hart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Oaks Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony John Scarsella, MD</last_name>
      <phone>310-967-3662</phone>
      <email>ascarsellaresearch@pacificoaks.com</email>
    </contact>
    <investigator>
      <last_name>Anthony John Scarsella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Lewin, MD</last_name>
      <phone>213-413-2500</phone>
      <email>docL@clinical-studies.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Lewin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Across America - Santa Ana</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N. Charle Morcos, MD</last_name>
      <phone>714-542-3008</phone>
      <phone_ext>315</phone_ext>
      <email>NCMorcosMD@gmail.com</email>
    </contact>
    <investigator>
      <last_name>N. Charle Morcos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Lipetz</last_name>
      <phone>619-660-9068</phone>
      <email>rlipetz@ecrstudies.com</email>
    </contact>
    <investigator>
      <last_name>Robert Lipetz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacksonville Impotence Treatment Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Miller, MD</last_name>
      <phone>904-260-8552</phone>
      <email>jagmanrm@aol.com</email>
    </contact>
    <investigator>
      <last_name>Roger Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Research East, LLC</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Block, MD</last_name>
      <phone>407-977-2705</phone>
      <email>compasseast.block@gmail.co</email>
    </contact>
    <investigator>
      <last_name>Bradley Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander White, MD</last_name>
      <phone>386-304-7070</phone>
      <email>dralexwhite@progressivemedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Alexander White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gigi Lefebvre, MD</last_name>
      <phone>727-347-8839</phone>
      <email>glefebvre@meridienresearch.net</email>
    </contact>
    <investigator>
      <last_name>Gigi Lefebvre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research- Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Huffman, MD</last_name>
      <phone>813-877-8839</phone>
      <email>chuffman@meridienresearch.net</email>
    </contact>
    <investigator>
      <last_name>Cynthia Huffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evanston Premier Healthcare Research LLC</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Geohas, MD</last_name>
      <phone>847-869-1191</phone>
      <email>jgeohas.ephr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Geohas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisphere Medical Research Center</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert Reyes, MD</last_name>
      <phone>812-471-4110</phone>
      <email>hreyes@medisphereresearch.com</email>
    </contact>
    <investigator>
      <last_name>Hubert Reyes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heartland Research Assoc., LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Hartvickson, MD</last_name>
      <phone>316-283-0828</phone>
      <email>rhartvickson@heartlandresearch.com</email>
    </contact>
    <investigator>
      <last_name>Robyn Hartvickson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisville Metabolic and Atherosclerosis Research Center (L-MARC)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harold Bays, MD</last_name>
      <phone>502-515-5672</phone>
      <email>hbaysmd@aol.com</email>
    </contact>
    <investigator>
      <last_name>Harold Bays, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Troy Internal Medicine, P.C.</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Fraser, MD</last_name>
      <phone>248-312-0025</phone>
      <email>nfraser@troyinternalmedicine.com</email>
    </contact>
    <investigator>
      <last_name>Neil Fraser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Edina</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Kotek, MD</last_name>
      <phone>952-922-7000</phone>
      <phone_ext>4600</phone_ext>
      <email>larrykotek@radiantresearch.com</email>
    </contact>
    <investigator>
      <last_name>Tami Helmer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Larry Kotek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peters Medical Research</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Jarrett</last_name>
      <phone>336-883-9773</phone>
      <email>thomasj@petersmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Jarrett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Rubino, MD</last_name>
      <phone>919-783-4895</phone>
      <email>jrubino@pmg-research.com</email>
    </contact>
    <investigator>
      <last_name>John Rubino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd. - Auburn</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew D Wenker, MD</last_name>
      <phone>513-381-4100</phone>
      <email>mwenker@sterlingresearch.org</email>
    </contact>
    <investigator>
      <last_name>Matthew D Wenker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metabolic and Atherosclerosis Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci A. Turner, MD, MT</last_name>
    </contact>
    <investigator>
      <last_name>Traci A. Turner, MD, MT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Clinical Research, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Arora, MD</last_name>
      <phone>614-501-6164</phone>
      <email>sarora@columbusclinical.com</email>
    </contact>
    <investigator>
      <last_name>Samir Arora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PSB Research/P. S. Bains, M.S., D.O.</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paramvir Bains, DO</last_name>
      <phone>614-537-0499</phone>
      <email>Bains000@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Paramvir Bains, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RAS Health Ltd</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chander Arora, MD</last_name>
      <phone>740-341-9943</phone>
      <email>chandera@aol.com</email>
    </contact>
    <investigator>
      <last_name>Arora Chander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Clinical Studies</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Buchanan, MD</last_name>
      <phone>541-461-0132</phone>
      <email>drpatb@aol.com</email>
    </contact>
    <investigator>
      <last_name>Patricia Buchanan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Green and Seidner Family Practice Associates</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Seidner, MD</last_name>
      <phone>215-361-7164</phone>
      <email>mrseidner@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Michael Seidner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Padre Coast Clinical Research</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Sandoval, MD</last_name>
      <phone>361-881-9300</phone>
      <email>padrecoast@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Jaime Sandoval, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Norfolk, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lubin Barry, MD</last_name>
      <phone>757-461-3633</phone>
      <email>blubin@ncrinc.net</email>
    </contact>
    <investigator>
      <last_name>Barry Lubin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Richmond, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James McKenney, PharmD</last_name>
      <phone>804-672-2133</phone>
      <phone_ext>12</phone_ext>
      <email>jmckenney@ncrinc.net</email>
    </contact>
    <investigator>
      <last_name>James McKenney, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>October 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
